Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910308 | 0.90 | AKR1B1 (0.46) | RIPK1APPMMP2MMP9MMP8 | |
| SCHEMBL8026684 | 0.84 | RIPK1 (0.44) | RIPK1APPMMP2MMP9MMP8 | |
| SCHEMBL27661443 | 0.83 | APP (0.52) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL9642062 | 0.80 | RIPK1 (0.55) | RIPK1APPMMP2MMP9MMP8 | |
| SCHEMBL201882 | 0.80 | RIPK1 (0.52) | RIPK1APPMMP2MMP9MMP8 | |
| SCHEMBL2141665 | 0.79 | APP (0.69) | RIPK1APPMMP2MMP9MMP8 | |
| SCHEMBL7544776 | 0.77 | MAPT (0.67) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL3190308 | 0.76 | KDM4E (0.51) | APPMMP9MMP8AKR1B1ALDH1A1 | |
| SCHEMBL5074923 | 0.76 | AKR1B1 (0.46) | AKR1B1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL28984552 | 0.76 | HDAC6 (0.55) | AKR1B1ALDH1A1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1571142-B1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA (IT) | 2012-09-12 | — | — | EP | disclosed |
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | MAKOVEC FRANCESCO | 2010-05-13 | — | — | US | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| EP-1654251-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| CN-100381502-C | Solid phase synthesis process of thiazde orange cyanine dye | TIANJIN CITY CONSTRUCTION COLL (CN) | 2008-04-16 | — | — | CN | disclosed |
| CN-1847321-A | Solid phase synthesis process of thiazde orange cyanine dye | TIANJIN CITY CONSTRUCTION COLL (CN) | 2006-10-18 | — | — | CN | disclosed |
| US-20060205740-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-09-14 | — | — | US | disclosed |
| EP-1654251-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005016914-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | NOS3, NOS1, NOS2 | RIPK1 3900/4885APP 2794/4885MMP2 532/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | RIPK1 3900/4885APP 2794/4885MMP2 532/4885 |
| US-20060205740-A1 | Chemical compounds | ERBB2, ERBB4, ERBB3 | RIPK1 833/4885APP 3244/4885MMP2 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.